Amoy Diagnostics 艾德生物
14 significant filings since 31 May 2026: 4 on change of control, 5 on buyback and 3 on change of interest, and 2 other kinds. The latest, on 16 Sep 2026: 关于公司董事、高级管理人员增持公司股份计划的公告.
自 31 May 2026 起有 14 份重大公告：change of control 4 份、buyback 5 份、change of interest 3 份，另有 2 类。最新一份（16 Sep 2026）：关于公司董事、高级管理人员增持公司股份计划的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 11 Aug 2024 | 国信证券 | 张佳博,张超 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 信达证券 | 唐爱金 | Unrated | 22 Apr 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。